Tags : Inflammatory Bowel Disease


Boehringer Ingelheim Collaborates with BiomX to Discover Microbiome-Based Biomarkers for

Shots: BiomX will generate metagenomic data of gut microbiome samples obtained from IBD patients with the focus of identifying biomarkers using the XMarker platform Boehringer Ingelheim gets an option to negotiate an exclusive right to biomarkers discovered under the collaboration. The XMarker platform supports the phage therapy for IBD, BX002, via analysis of real-world metagenomic […]Read More

Biosimilars Regulatory

Celltrion’s Remsima SC (biosimilar, infliximab) Receives CHMP’s Positive Opinion for

Shots: CHMP has recommended expanding the existing marketing authorization for Remsima SC for five indications that include AS, CD, UC, PsA and psoriasis. The CHMP’s positive opinion follows EC’s MAA for the therapy granted in Nov’2019 The CHMP’s opinion is based on data evaluating the PK, efficacy and safety between CT-P13 SC to CT-P13 IV […]Read More


Synlogic Terminates its Agreement with AbbVie for Synthetic Biotic Medicines

Shots: Synlogic regains all rights to develop Synthetic Biotic medicines for all effectors targeting IBD. The termination allows Synlogic to deploy its expertise in strain engineering, quantitative biology, regulatory, and manufacturing of living medicines for expanding its wholly GI-based program portfolio to include IBD Regaining WW rights to develop treatments for IBD allows Synlogic to […]Read More


Gilead Sciences and Second Genome Signs a Four-Year Collaboration to

Shots: Second Genome will receive $38M as upfront, up to $300M milestones for each of five target discovery programs and royalties for approved therapies. Additionally, it will receive milestones for each validated biomarker delivered under the collaboration The collaboration will deploy Second Genome’s Microbiome Analytics Platform to identify biomarkers associated with clinical response in up […]Read More


Takeda Signs Multi-Target Strategic Collaboration with Prometheus to Develop Targeted

Shots: Prometheus to receive up front, $420M as development, regulatory & commercial milestone with royalties on sales of each program and will be responsible for the identification and validation of three unique drug targets. Takeda to discover, develop & commercialize up to three targeted IBD therapeutics and companion diagnostics The collaboration combines Prometheus’ bioinformatics analysis […]Read More


Salix (Bausch Health) Signs an Exclusive License Agreement with Mitsubishi

Shots: MTPC to receive upfront, development & regulatory milestones and royalties on sales. Bausch Health to get exclusive WW rights to develop & commercialize MT-1303 (Ex-Japan & few other countries in Asia) in all fields (Ex. neurology, rheumatology and certain rare dermatology diseases) Bausch plans to initiate the development of MTPC’s MT-1303 (amiselimod) in ulcerative […]Read More